Valvular & structural heart disease

Prognosis of tricuspid regurgitation after mitral transcatheter edge-to-edge repair: the EXPANDed studies

ESC Heart FailPublished pooled cohort from the EXPAND and EXPAND G4 studies

Authors' conclusion

Early TR improvement to ≤moderate was observed in almost 3/4 of the population and was associated with significant symptomatic relief. Patients with both severe MR and TR, particularly those with LV dilation, may experience TR improvement following MTEER.

Study context

Population
Patients with severe tricuspid regurgitation (TR) who achieved procedural success with mitral transcatheter edge-to-edge repair (MTEER) with the MitraClip System and received no direct TR interventionevaluable TR data at 30 days
Participants
160 patients
Exposure
30-day TR severity following MTEER: ≤moderate TR vs ≥severe TR
  • ≤moderate TRn = 116
  • ≥severe TRn = 44
Methodological detailsecho core lab
  • Echo core lab

Main finding

As reported in the abstract

TR severity at 30 days · 30 days

Observational data: associations, not effects.

Further findings

Baseline atrial fibrillation

Baseline LV ejection fraction

One-year mortality

Baseline LVEDV

Outcome≤moderate TR≥severe TR
TR at 1 yearTR reduction sustained 86%improved to ≤moderate 45%
  • Baseline atrial fibrillation: P = .009
  • Baseline LV ejection fraction: P = .07
  • Baseline LVEDV: P = .01
  • One-year mortality: HR = 1.92 [.77, 4.79], P = .16 (not statistically significant)

NYHA functional class and KCCQ-OS score (≤moderate TR group) · through 1 year

NYHA functional class improvement P
P < 0.0001
KCCQ-OS score Δ
+ 30.6 ± 25.7, P < .0001

Associations with TR improvement post-MTEER

Lower LVEF and larger baseline LV size were associated with TR improvement

Original publication

Prognosis of tricuspid regurgitation after mitral transcatheter edge-to-edge repair: the EXPANDed studies. ESC Heart Fail. Published 16 April 2026. doi:10.1093/eschf/xvag108

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.